CA
NZ
UK
AU
IND
US
Johnson & Johnson (NYSE:JNJ) reported third-quarter sales of USD 25.4 billion, up 5.9%, on October 13, 2026 and lifted its full-year adjusted EPS outlook to USD 11.05 to USD 11.15. Even so, the shares fell between 5.34% and 6% at the close, after opening …
UnitedHealth Group (NYSE:UNH) reported third-quarter EPS of USD 4.69 on October 13, 2026, against a consensus of USD 4.06, and raised its 2026 EPS guidance to at least USD 20.50. The beat of USD 0.63 a share is about 15.5% above the estimate, simple …
Syndax Pharmaceuticals (NASDAQ:SNDX) announced on October 13, 2026 that its axatilimab trial in lung disease missed the Phase 2 primary endpoint and that the trials were discontinued. The shares fell more than 17%, the stock's sharpest one-day drop since May 2025. Axatilimab is an …
Shares of Pinnacle Food Group Limited climbed about 80% on Tuesday to close at $4.70, with volume well above average. The spark was news that its subsidiary completed the first bench-scale fermentation of its first-generation recombinant human lactoferrin (rhLF) yeast strain in a 5-liter …
SCWorx Corp. fell about 22% on Tuesday to close at $2.46, a volatile stretch since the healthcare data-management software company regained Nasdaq compliance and resumed trading after a multi-month suspension. Pre-market today the stock was down roughly 11% near $2.18. Selling pressure reflects dilution …
Nexalin Technology, Inc. declined about 21% on Tuesday to close at $2.64, continuing a longer downtrend for the medical-device micro-cap focused on neurostimulation products. Pre-market today the stock was roughly flat to slightly lower near $2.61. The stock remains under pressure from ongoing losses, …
Capricor Therapeutics, Inc. (NASDAQ:CAPR)'s second quarter reflected continuedInvestmentin its Deramiocel regulatory program as the company's net loss widened from a year earlier. Management said it is continuing to work with the FDA on a path forward for theBiologicsLicense Application following a July 29, 2026 …
Evolent Health, Inc. (NYSE:EVH)'s second quarter combined sharply higher revenue and Adjusted EBITDA with a net loss, as its Performance Suite segment grew and the company raised its full-year 2026 outlook. Co-Founder and Chief Executive Officer Seth Blackley said the company's results, updated 2026 …
Sarepta Therapeutics, Inc. (NASDAQ:SRPT)'s second quarter combined continued operating profitability with a sharp decline in total revenue, driven primarily by lower sales of its gene therapy Elevidys following prior safety events and a label change restricting its use to ambulatory patients. New Chief Executive …
● Non-GAAP earnings per share were $1.62, up from $1.37.
Please wait processing your request...